CD8A and cancer: A retrospective study showed that CD8 + T‐cell abundance was the most predictive parameter of the response to anti‐PD‐1/PD‐L1 therapy across many cancer types,12 and the ratio of CD8 + TILs was significantly lower in EGFR‐mutant than in wild‐type patients.10, 13